Anti-inflammatory therapies for atherosclerosis (original) (raw)

• Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685–1695 (2005).
  Article CAS PubMed Google Scholar
• Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317–325 (2011).
  Article CAS PubMed Google Scholar
• Jonasson, L., Holm, J., Skalli, O., Gabbiani, G. & Hansson, G. K. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest. 76, 125–131 (1985).
  Article CAS PubMed PubMed Central Google Scholar
• Hansson, G. K., Hellstrand, M., Rymo, L., Rubbia, L. & Gabbiani, G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med. 170, 1595–1608 (1989).
  Article CAS PubMed Google Scholar
• Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135–1143 (2002).
  Article CAS PubMed Google Scholar
• Palinski, W. et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl Acad. Sci. USA 86, 1372–1376 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Stemme, S. et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl Acad. Sci. USA 92, 3893–3897 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Mach, F., Schonbeck, U., Sukhova, G. K., Atkinson, E. & Libby, P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394, 200–203 (1998).
  Article CAS PubMed Google Scholar
• Nicoletti, A., Kaveri, S., Caligiuri, G., Bariety, J. & Hansson, G. K. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J. Clin. Invest. 102, 910–918 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Hansson, G. K. & Hermansson, A. The immune system in atherosclerosis. Nat. Immunol. 12, 204–212 (2011).
  Article CAS PubMed Google Scholar
• Jonasson, L., Holm, J. & Hansson, G. K. Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc. Natl Acad. Sci. USA 85, 2303–2306 (1988).
  Article CAS PubMed PubMed Central Google Scholar
• Marks, A. R. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N. Engl. J. Med. 349, 1307–1309 (2003).
  Article CAS PubMed Google Scholar
• Lutgens, E. et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J. Exp. Med. 207, 391–404 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Chatzigeorgiou, A. et al. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc. Natl Acad. Sci. USA 111, 2686–2691 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Cutolo, M., Sulli, A., Pizzorni, C., Seriolo, B. & Straub, R. H. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 60, 729–735 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Bulgarelli, A., Martins Dias, A. A., Caramelli, B. & Maranhao, R. C. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J. Cardiovasc. Pharmacol. 59, 308–314 (2012).
  Article CAS PubMed Google Scholar
• Westlake, S. L. et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 49, 295–307 (2010).
  Article CAS Google Scholar
• Micha, R. et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am. J. Cardiol. 108, 1362–1370 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ahlehoff, O. et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J. Intern. Med. 273, 197–204 (2013).
  Article CAS PubMed Google Scholar
• Everett, B. M. et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am. Heart J. 166, 199–207.e15 (2013).
  Article PubMed PubMed Central Google Scholar
• Nidorf, S. M., Eikelboom, J. W. & Thompson, P. L. Colchicine for secondary prevention of cardiovascular disease. Curr. Atheroscler. Rep. 16, 391 (2014).
  Article CAS PubMed Google Scholar
• Nuki, G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr. Rheumatol. Rep. 10, 218–227 (2008).
  Article CAS PubMed Google Scholar
• Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
  Article CAS PubMed Google Scholar
• Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Crittenden, D. B. et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J. Rheumatol. 39, 1458–1464 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Grimaldi-Bensouda, L. et al. Impact of allopurinol on risk of myocardial infarction. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-202972.
• Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A. & Thompson, P. L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 61, 404–410 (2013).
  Article CAS PubMed Google Scholar
• Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597–605 (2011).
  Article CAS PubMed Google Scholar
• Kaya, E. B. et al. Serum uric acid levels predict the severity and morphology of coronary atherosclerosis detected by multidetector computed tomography. Atherosclerosis 213, 178–183 (2010).
  Article CAS PubMed Google Scholar
• Higgins, P. et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc. Ther. 30, 217–226 (2012).
  Article CAS PubMed Google Scholar
• George, J., Carr, E., Davies, J., Belch, J. J. & Struthers, A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114, 2508–2516 (2006).
  Article CAS PubMed Google Scholar
• Kushiyama, A. et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler. Thromb. Vasc. Biol. 32, 291–298 (2012).
  Article CAS PubMed Google Scholar
• Noman, A., Ang, D. S., Ogston, S., Lang, C. C. & Struthers, A. D. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375, 2161–2167 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Rentoukas, E. et al. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int. J. Cardiol. 145, 257–258 (2010).
  Article CAS PubMed Google Scholar
• Topol, E. J. et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 343, 881–886 (1994).
  Article CAS PubMed Google Scholar
• Wallberg-Jonsson, S., Ohman, M. L. & Dahlqvist, S. R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J. Rheumatol. 24, 445–451 (1997).
  CAS PubMed Google Scholar
• Holmqvist, M. E. et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum. 60, 2861–2869 (2009).
  Article PubMed Google Scholar
• Taylor, P. C. & Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 578–582 (2009).
  Article CAS PubMed Google Scholar
• Jacobsson, L. T. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213–1218 (2005).
  CAS PubMed Google Scholar
• Dixon, W. G. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905–2912 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Bevilacqua, M. P., Pober, J. S., Majeau, G. R., Cotran, R. S. & Gimbrone, M. A. Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 160, 618–623 (1984).
  Article CAS PubMed Google Scholar
• Libby, P., Warner, S. J. & Friedman, G. B. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J. Clin. Invest. 81, 487–98 (1988).
  Article CAS PubMed PubMed Central Google Scholar
• Rajamaki, K. et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5, e11765 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ridker, P. M. et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126, 2739–2748 (2012).
  Article CAS PubMed Google Scholar
• Lee, T. S., Yen, H. C., Pan, C. C. & Chau, L. Y. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19, 734–742 (1999).
  Article CAS PubMed Google Scholar
• Davenport, P. & Tipping, P. G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163, 1117–1125 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Yong, K. et al. Interleukin-12 is associated with arterial stiffness in healthy individuals. Am. J. Hypertens. 26, 159–162 (2013).
  Article CAS PubMed Google Scholar
• David, A. et al. Interleukin-23 serum levels in patients affected by peripheral arterial disease. Clin. Biochem. 45, 275–258 (2012).
  Article CAS PubMed Google Scholar
• Gistera, A. et al. Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci. Transl. Med. 5, 196ra100 (2013).
  Article CAS PubMed Google Scholar
• Ryan, C. et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306, 864–871 (2011).
  CAS PubMed Google Scholar
• Tzellos, T., Kyrgidis, A. & Zouboulis, C. C. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J. Eur. Acad. Dermatol. Venereol. 27, 622–627 (2013).
  Article CAS PubMed Google Scholar
• Koenen, R. R. & Weber, C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol. Med. 3, 713–725 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Boring, L., Gosling, J., Cleary, M. & Charo, I. F. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894–897 (1998).
  Article CAS PubMed Google Scholar
• Gilbert, J. et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am. J. Cardiol. 107, 906–911 (2011).
  Article CAS PubMed Google Scholar
• Weber, C. et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J. Clin. Invest. 121, 2898–2910 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Burke, J. E. & Dennis, E. A. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid. Res. 50 (Suppl.), S237–S242 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenson, R. S. & Gelb, M. H. Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Curr. Cardiol. Rep. 11, 445–451 (2009).
  Article PubMed Google Scholar
• Suckling, K. E. Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin. Investig. Drugs 18, 1425–1430 (2009).
  Article CAS PubMed Google Scholar
• Rosenson, R. S. & Hurt-Camejo, E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur. Heart J. 33, 2899–2909 (2012).
  Article CAS PubMed Google Scholar
• Fraser, H. et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE−/− mice. J. Cardiovasc. Pharmacol. 53, 60–65 (2009).
  Article CAS PubMed Google Scholar
• Shaposhnik, Z., Wang, X., Trias, J., Fraser, H. & Lusis, A. J. The synergistic inhibition of atherogenesis in apoE−/− mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J. Lipid Res. 50, 623–629 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenson, R. S. et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J. Am. Coll. Cardiol. 56, 1079–1088 (2010).
  Article CAS PubMed Google Scholar
• Nicholls, S. J. et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 311, 252–262 (2014).
  Article CAS PubMed Google Scholar
• Ait-Oufella, H. et al. Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 33, 466–473 (2013).
  Article CAS PubMed Google Scholar
• Tsimikas, S., Tsironis, L. D. & Tselepis, A. D. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 27, 2094–2099 (2007).
  Article CAS PubMed Google Scholar
• Kolodgie, F. D. et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2523–2529 (2006).
  Article CAS PubMed Google Scholar
• Wilensky, R. L. et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 14, 1059–1066 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Serruys, P. W. et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118, 1172–1182 (2008).
  Article CAS PubMed Google Scholar
• STABILITY Investigators. Darapladib for preventing ischemic events in stable coronary heart disease. N. Engl. J. Med. 370, 1702–1711 (2014).
• O'Donoghue, M. L. et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID–TIMI 52 randomized clinical trial. JAMA 312, 1006–1015 (2014).
  Article CAS PubMed Google Scholar
• Capra, V., Bäck, M., Angiolillo, D. J., Cattaneo, M. & Sakariassen, K. S. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J. Thromb. Haemost. 12, 126–137 (2014).
  Article CAS PubMed Google Scholar
• Gabrielsen, A. et al. Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion. J. Mol. Med. (Berl.) 88, 795–806 (2010).
  Article CAS Google Scholar
• Petri, M. H. et al. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 441, 393–398 (2013).
  Article CAS PubMed Google Scholar
• Bousser, M. G. et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 377, 2013–2022 (2011).
  Article CAS PubMed Google Scholar
• Stemme, V., Swedenborg, J., Claesson, H. & Hansson, G. K. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur. J. Vasc. Endovasc. Surg. 20, 146–152 (2000).
  Article CAS PubMed Google Scholar
• Bäck, M., Yin, L. & Ingelsson, E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur. Heart J. 33, 1928–1933 (2012).
  Article CAS PubMed Google Scholar
• Foudi, N. et al. Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits. Am. J. Physiol. Heart Circ. Physiol. 297, H1882–H1888 (2009).
  Article CAS PubMed Google Scholar
• Hui, Y. et al. Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation 121, 2654–2660 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tang, S. Y. et al. Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice. Circulation 129, 1761–1769 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Babaev, V. R. et al. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 113, 108–117 (2006).
  Article CAS PubMed Google Scholar
• Rådmark, O. & Samuelsson, B. Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem. Biophys. Res. Commun. 396, 105–110 (2010).
  Article CAS PubMed Google Scholar
• Bäck, M. et al. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br. J. Pharmacol. 171, 3551–3574 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Bäck, M. & Hansson, G. K. Leukotriene receptors in atherosclerosis. Ann. Med. 38, 493–502 (2006).
  Article CAS PubMed Google Scholar
• Nagy, E. et al. Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 123, 1316–1325 (2011).
  Article CAS PubMed Google Scholar
• Bäck, M., Gasser, T. C., Michel, J. B. & Caligiuri, G. Biomechanical factors in the biology of aortic wall and aortic valve diseases. Cardiovasc. Res. 99, 232–241 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kwak, B. R. et al. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. Eur. Heart J. 14, 3013–3020 (2014).
  Article CAS Google Scholar
• Otsuka, F., Sakakura, K., Yahagi, K., Joner, M. & Virmani, R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler. Thromb. Vasc. Biol. 34, 724–736 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Spanbroek, R. et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl Acad. Sci. USA 100, 1238–1243 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Allen, S., Dashwood, M., Morrison, K. & Yacoub, M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 97, 2406–2413 (1998).
  Article CAS PubMed Google Scholar
• De Caterina, R. et al. Sulfido-peptide leukotrienes in coronary heart disease—relationship with disease instability and myocardial ischaemia. Eur. J. Clin. Invest. 40, 258–272 (2010).
  Article CAS PubMed Google Scholar
• Labat, C. et al. Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis. J. Hypertens. 31, 2251–2258 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Stanke-Labesque, F. et al. Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J. Lipid Res. 53, 1944–1951 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Bäck, M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr. Pharm. Des. 15, 3116–3132 (2009).
  Article PubMed Google Scholar
• Jawien, J. et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur. J. Clin. Invest. 36, 141–146 (2006).
  Article CAS PubMed Google Scholar
• Bäck, M., Sultan, A., Ovchinnikova, O. & Hansson, G. K. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ. Res. 100, 946–949 (2007).
  Article CAS PubMed Google Scholar
• Yu, Z. et al. Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc. Natl Acad. Sci. USA 109, 6727–6732 (2012).
  Article PubMed PubMed Central Google Scholar
• Bäck, M. et al. Leukotriene B4 signaling through NF-κB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc. Natl Acad. Sci. USA 102, 17501–17506 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Heller, E. A. et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 112, 578–586 (2005).
  Article PubMed Google Scholar
• Hlawaty, H. et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler. Thromb. Vasc. Biol. 29, 518–524 (2009).
  Article CAS PubMed Google Scholar
• Mueller, C. F. et al. Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation 117, 2912–2918 (2008).
  Article CAS PubMed Google Scholar
• Allayee, H. et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest 132, 868–874 (2007).
  Article CAS PubMed Google Scholar
• Ingelsson, E., Yin, L. & Bäck, M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J. Allergy Clin. Immunol. 129, 702–707 e2 (2012).
  Article CAS PubMed Google Scholar
• Hakonarson, H. et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293, 2245–2256 (2005).
  Article CAS PubMed Google Scholar
• Tardif, J. C. et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ. Cardiovasc. Imaging 3, 298–307 (2010).
  Article PubMed Google Scholar
• Liu, H. Q. et al. NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 33, 2193–2201 (2013).
  Article CAS PubMed Google Scholar
• Bitto, A. et al. Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques. J. Vasc. Surg. 52, 1015–1021 (2010).
  Article PubMed Google Scholar
• Seeger, F. H. et al. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res. Cardiol. 105, 389–397 (2010).
  Article CAS PubMed Google Scholar
• Morris, J. B. et al. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler. Thromb. Vasc. Biol. 28, 265–271 (2008).
  Article CAS PubMed Google Scholar
• Fisk, M., Gajendragadkar, P. R., Maki-Petaja, K. M., Wilkinson, I. B. & Cheriyan, J. Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease. Am. J. Cardiovasc. Drugs 14, 155–165 (2014).
  Article CAS PubMed Google Scholar
• Sarov-Blat, L. et al. Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans. Arterioscler. Thromb. Vasc. Biol. 30, 2256–2263 (2010).
  Article CAS PubMed Google Scholar
• Natarajan, P. & Cannon, C. P. Could direct inhibition of inflammation be the “next big thing” in treating atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 30, 2081–2083 (2010).
  Article CAS PubMed Google Scholar
• Cheriyan, J. et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 123, 515–523 (2011).
  Article CAS PubMed Google Scholar
• Elkhawad, M. et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc. Imaging 5, 911–922 (2012).
  Article PubMed Google Scholar
• Melloni, C. et al. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. Am. Heart J. 164, 646–653.e3 (2012).
  Article CAS PubMed Google Scholar
• Newby, L. K. et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 384, 1187–1195 (2014).
  Article CAS PubMed Google Scholar
• Parmar, K. M. et al. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J. Biol. Chem. 280, 26714–26719 (2005).
  Article CAS PubMed Google Scholar
• Ali, F. et al. Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow. J. Biol. Chem. 284, 18882–18892 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• van Thienen, J. V. et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovasc. Res. 72, 231–240 (2006).
  Article CAS PubMed Google Scholar
• Sorescu, D. et al. Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation 105, 1429–1435 (2002).
  Article CAS PubMed Google Scholar
• Guzik, T. J. et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105, 1656–1662 (2002).
  Article CAS PubMed Google Scholar
• Sheehan, A. L. et al. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 216, 321–326 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Judkins, C. P. et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE−/− mice. Am. J. Physiol. Heart Circ. Physiol. 298, H24–H32 (2010).
  Article CAS PubMed Google Scholar
• Gray, S. P. et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127, 1888–1902 (2013).
  Article CAS PubMed Google Scholar
• Di Marco, E. et al. Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe −/− mice. Diabetologia 57, 633–642 (2014).
  Article CAS PubMed Google Scholar
• Iida, O. et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 127, 2307–2315 (2013).
  Article CAS PubMed Google Scholar
• Douglas, J. S. Jr et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 112, 2826–2832 (2005).
  Article CAS PubMed Google Scholar
• Souness, J. E., Hassall, G. A. & Parrott, D. P. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 44, 857–866 (1992).
  Article CAS PubMed Google Scholar
• Ishizaka, N. et al. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 142, 41–46 (1999).
  Article CAS PubMed Google Scholar
• Takase, H. et al. Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Arzneimittelforschung 57, 185–191 (2007).
  CAS PubMed Google Scholar
• Beghe, B., Rabe, K. F. & Fabbri, L. M. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am. J. Respir. Crit. Care Med. 188, 271–278 (2013).
  Article CAS PubMed Google Scholar
• White, W. B. et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 144, 758–765 (2013).
  Article CAS PubMed Google Scholar
• Balarini, C. M. et al. Sildenafil restores endothelial function in the apolipoprotein E knockout mouse. J. Transl. Med. 11, 3 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Xu, Q., Kleindienst, R., Waitz, W., Dietrich, H. & Wick, G. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J. Clin. Invest. 91, 2693–2702 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Palinski, W., Miller, E. & Witztum, J. L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl Acad. Sci. USA 92, 821–825 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Ameli, S. et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16, 1074–1079 (1996).
  Article CAS PubMed Google Scholar
• George, J. et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138, 147–152 (1998).
  Article CAS PubMed Google Scholar
• Zhou, X., Caligiuri, G., Hamsten, A., Lefvert, A. K. & Hansson, G. K. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21, 108–114 (2001).
  Article CAS PubMed Google Scholar
• Ketelhuth, D. F., Gistera, A., Johansson, D. K. & Hansson, G. K. T cell-based therapies for atherosclerosis. Curr. Pharm. Des. 19, 5850–5858 (2013).
  Article CAS PubMed Google Scholar
• van Puijvelde, G. H. et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114, 1968–1976 (2006).
  Article CAS PubMed Google Scholar
• Klingenberg, R. et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30, 946–952 (2010).
  Article CAS PubMed Google Scholar
• Shah, P. K., Chyu, K., Dimayuga, P. C. & Nilsson, J. Vaccine for atherosclerosis. J. Am. Coll. Cardiol. 64, 2779–2791 (2014).
  Article CAS PubMed Google Scholar
• Xu, Q. et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. 12, 789–799 (1992).
  Article CAS PubMed Google Scholar
• George, J. et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler. Thromb. Vasc. Biol. 19, 505–510 (1999).
  Article CAS PubMed Google Scholar
• Maron, R. et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106, 1708–1715 (2002).
  Article CAS PubMed Google Scholar
• Ait-Oufella, H. et al. Measles virus nucleoprotein induces a regulatory immune response and reduces atherosclerosis in mice. Circulation 116, 1707–1713 (2007).
  Article PubMed Google Scholar
• Ovchinnikova, O. A. et al. Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis. J. Intern. Med. 275, 49–58 (2014).
  Article CAS PubMed Google Scholar